Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT07450547

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Led by Anagram Therapeutics, Inc. · Updated on 2026-05-08

113

Participants Needed

26

Research Sites

61 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.

CONDITIONS

Official Title

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female subjects aged 12 years or older in the US and 18 years or older in the EU
  • Confirmed and documented diagnosis of cystic fibrosis
  • Diagnosed with severe exocrine pancreatic insufficiency defined by fecal elastase ≤50 µg/g stool at screening
  • Controlled exocrine pancreatic insufficiency and stable dose of pancreatic enzyme replacement therapy for 90 days prior to screening
  • Adequate nutritional status measured by BMI: ≥25th percentile for children aged 12-17 years or ≥18.5 kg/m2 for adults 18 years and older
Not Eligible

You will not qualify if you...

  • History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of screening
  • History of lung or liver transplant, listing for organ transplant, or significant bowel resection within the last 6 months (except resections not causing short bowel syndrome)
  • Known severe allergic reaction to any ingredient of the study drug ANG003, Creon, or the stool marker FD&C Blue #2
  • Any chronic diarrheal illness unrelated to pancreatic insufficiency
  • Currently treated for small intestinal bacterial overgrowth
  • Use of naso-gastric, J-tube, G-tube, or enteral feeding during the study
  • Clostridioides difficile infection within 6 months prior to screening
  • Severe constipation defined as fewer than 1 bowel movement per week

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 26 locations

1

Long Beach Memorial Medical Center

Long Beach, California, United States, 90806

Not Yet Recruiting

2

Center for Cystic Fibrosis at Keck Medical Center of USC

Los Angeles, California, United States, 90033

Not Yet Recruiting

3

National Jewish Health

Denver, Colorado, United States, 80206

Not Yet Recruiting

4

University of Florida

Gainesville, Florida, United States, 32610

Not Yet Recruiting

5

Central Florida Pulmonary Group

Orlando, Florida, United States, 32803

Not Yet Recruiting

6

The Cystic Fibrosis Institute

Glenview, Illinois, United States, 60025

Actively Recruiting

7

University of Iowa

Iowa City, Iowa, United States, 52242

Not Yet Recruiting

8

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Not Yet Recruiting

9

University of Kentucky

Lexington, Kentucky, United States, 40506

Not Yet Recruiting

10

MaineHealth Pediatric Specialty Care

Portland, Maine, United States, 04102

Not Yet Recruiting

11

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Not Yet Recruiting

12

Boston Children's Hospita

Boston, Massachusetts, United States, 02115

Not Yet Recruiting

13

University of Michigan, Michigan Medicine

Ann Arbor, Michigan, United States, 48109

Not Yet Recruiting

14

Wayne State University Harper University Hospital

Detroit, Michigan, United States, 48201

Not Yet Recruiting

15

Rutgers - Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States, 08903

Not Yet Recruiting

16

New York Medical College at Westchester Medical Center

Valhalla, New York, United States, 10595

Not Yet Recruiting

17

Children's Hospital Medical Center of Akron

Akron, Ohio, United States, 44308

Not Yet Recruiting

18

Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States, 44106

Not Yet Recruiting

19

Nationwide Children's Hospital, Columbus

Columbus, Ohio, United States, 43205

Not Yet Recruiting

20

Toledo Children's Hospital

Toledo, Ohio, United States, 43606

Not Yet Recruiting

21

Hershey Medical Center Pennsylvania State University

Hershey, Pennsylvania, United States, 17033

Not Yet Recruiting

22

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States, 15224

Not Yet Recruiting

23

University of Texas Southwestern / Children's Health

Dallas, Texas, United States, 75207

Not Yet Recruiting

24

Adult Cystic Fibrosis Center at the University of Utah

Salt Lake City, Utah, United States, 84112

Not Yet Recruiting

25

University of Wisconsin

Madison, Wisconsin, United States, 53792

Not Yet Recruiting

26

Froedtert & Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Not Yet Recruiting

Loading map...

Research Team

E

Evan Bailey, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here